Valeant to become Bausch Health Companies in rebrand

Posted in Biotech

May 08, 2018

Takeda Buys Shire For $62 Billion Creating Pharma Giant

Posted in Biotech

May 08, 2018

Revance Therapeutics Investor Day Deck

Posted in Biotech

May 07, 2018 • 3 min read

​The following Investor Day deck was published by Revance Therapeutics. Revance is expected to release earnings on May 8, 2018 at 4:30 PM ET. We will be covering their earnings release. ...

If approved by the FDA, esketamine would become one of the first new approaches to treat refractory major depressive disorder in the last 50 years.

Posted in Biotech

May 07, 2018

A life sciences firm run by a top VC and a cofounder of Alphabet’s life sciences arm, just raised its biggest fund yet

Posted in Biotech

May 06, 2018

Allergan focuses on men to grow Botox franchise

Posted in Biotech

May 04, 2018 • 3 min read

Earlier this week, Allergan ($AGN) released earnings to mixed reviews from investors. In the past year, the stock has fallen from its 52 week high of ~$256 to its current levels of ~$148. This decline has put pressure on the management team to make changes and perform as Botox competition is looming and they are trying to navigate their Restasis patent expiration strategy, which up to this point, has not gone so smoothly. In an effort to calm investor concerns, Allergan CEO, Brent Saunders, ...

Allergan CEO sits down with Mad Money's Jim Cramer

Posted in Biotech

May 01, 2018 • 3 min read

Allergan CEO, Brent Saunders, was on Mad Money with Jim Cramer last night to discuss Allergan earnings and their pipeline, specifically, Rapastinel, a potentially game changing depression drug. ...